Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30886508 | 0.74 | DYRK1A (0.55) | DYRK1ASCN5ATGFBR1JAK2PIK3CD | |
| SCHEMBL421292 | 0.74 | DYRK1A (0.47) | DYRK1ASCN5ATGFBR1MAP4K4PIK3CD | |
| SCHEMBL21104073 | 0.74 | DYRK1A (0.47) | DYRK1ASCN5ATGFBR1MAP4K4PIK3CD | |
| SCHEMBL19023337 | 0.74 | DYRK1A (0.47) | DYRK1ASCN5ATGFBR1PIK3CDPDE4B | |
| SCHEMBL18077230 | 0.74 | SCN5A (0.47) | DYRK1ASCN5ATGFBR1MAP4K4JAK2 | |
| SCHEMBL3326856 | 0.74 | DYRK1A (0.47) | DYRK1ASCN5ATGFBR1MAP4K4PIK3CD | |
| SCHEMBL5741141 | 0.74 | DYRK1A (0.47) | DYRK1ASCN5ATGFBR1PIK3CDEGLN2 | |
| SCHEMBL3326861 | 0.74 | DYRK1A (0.47) | DYRK1ASCN5ATGFBR1PIK3CDEGLN2 | |
| SCHEMBL1585961 | 0.74 | DYRK1A (0.47) | DYRK1ASCN5ATGFBR1MAP4K4PIK3CD | |
| SCHEMBL2177498 | 0.74 | KEAP1 (0.49) | DYRK1ASCN5ATGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096710-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-12-26 | — | — | US | disclosed |
| CN-112513029-B | Nitrogen-containing aryl phosphorus oxide derivative, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| EP-3898633-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2021-10-27 | — | — | EP | disclosed |
| WO-2018110669-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-21 | — | — | WO | disclosed |
| US-20170260632-A1 | ETCHANT, REPLENISHMENT SOLUTION AND METHOD FOR FORMING COPPER WIRING | MEC COMPANY LTD. (JP) | 2017-09-14 | — | — | US | disclosed |
| EP-2651931-B1 | FUSED DIHYDROPYRANS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY AND RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| WO-2009122180-A1 | PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES | MEDICAL RESEARCH COUNCIL (GB) | 2009-10-08 | — | — | WO | disclosed |
| US-7273863-B1 | Benzophenones as inhibitors of reverse transcriptase | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1710238-A1 | Benzophenones as inhibitors of reverse transcriptase | GLAXO GROUP LIMITED (GB) | 2006-10-11 | — | — | EP | disclosed |
| EP-1208091-A1 | BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE | GLAXO GROUP LIMITED (GB) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001017982-A1 | BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE | GLAXO GROUP LIMITED (GB) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | DYRK1A 4810/4885SCN5A 2300/4885TGFBR1 448/4885 |
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | NLRP3, PYCARD, NLRP1 | DYRK1A 4764/4885SCN5A 490/4885TGFBR1 731/4885 |
| US-20100056524-A1 | Compound | NR3C2, NR3C1, NR2E3 | DYRK1A 749/4885SCN5A 719/4885TGFBR1 229/4885 |
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | KCNJ11, KCNJ1, KCNJ8 | DYRK1A 3429/4885SCN5A 95/4885TGFBR1 4297/4885 |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | KCNJ11, KCNJ1, KCNJ8 | DYRK1A 3429/4885SCN5A 95/4885TGFBR1 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.